Eduardo M. Sotomayor, MD

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  Johns Hopkins Oncology Center - Oncology
          •  Department of Microbiology & Immunology, University of Miami, School of Medicine - Immunology

RESIDENCY:
          •  University of Miami School of Medicine - Internal Medicine

MEDICAL SCHOOL:
          •  Federico Villarreal University School of Medicine, Lima, Peru - MD

• Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.


• Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.


• Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Mar. Pubmedid: 23538750.


• Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan;54(1):205-208. Pubmedid: 22694793.


• Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov;55(22):9891-9899. Pubmedid: 23009203. Pmcid: PMC3562128.


• Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K. Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells. Clin Cancer Res. 2012 Nov;18(22):6227-6238. Pubmedid: 22932665.


• Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012 Oct;120(5):1027-1038. Pubmedid: 22692508.


• Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct;22(4):506-523. Pubmedid: 23079660.


• Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity. Cancer Res. 2012 Sep;72(17):4440-4448. Pubmedid: 22728650.


• Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control. 2012 Jul;19(3):227-235. Pubmedid: 22710898.


• Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012 Jun;31(24):3002-3008. Pubmedid: 22002311.


• Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr;61(4):523-533. Pubmedid: 21983879.


• Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 2012 Jan;90(1):55-65. Pubmedid: 22105512.


• Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.


• Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leuk Res. 2011 Nov;35(9):1193-1199. Pubmedid: 21377729.


• Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011 Sep;29(20):2787-2794. Pubmedid: 21632504. Pmcid: PMC3139394.


• Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug;86(8):663-667. Pubmedid: 21761432.


• Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.


• Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res. 2011 May;35(3):394-404. Pubmedid: 20863567.


• Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr;186(7):3986-3996. Pubmedid: 21368229.


• Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr;52(4):668-679. Pubmedid: 21271862.


• Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res. 2011 Mar;16(19):4742-4754. Pubmedid: 20647473. Pmcid: PMC2948590.


• Beltran BE, Castillo JJ, Salas R, Qui?ones P, Morales D, Cotrina E, Miranda RN, Sotomayor EM. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. Leuk Lymphoma. 2011 Jan;52(1):153-156. Pubmedid: 21219127.


• Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2011 Jan;25(1):145-152. Pubmedid: 20966935. Pmcid: PMC3083119.


• Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2011 Jan;116(24):5228-5236. Pubmedid: 20841506. Pmcid: PMC3012540.


• Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010 Nov;28(31):e629-e632. Pubmedid: 20733121.


• Sotomayor EM. "Skulls and bones" new member: Th17. Blood. 2010 Nov;116(18):3380-3382. Pubmedid: 21051562.


• Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul;131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.


• Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010 Jun;8(6):907-918. Pubmedid: 20530581. Pmcid: PMC2891394.


• Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, Chen J, Lane WS, Seto E. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol. 2010 Jun;30(12):3004-3015. Pubmedid: 20368352. Pmcid: PMC2876676.


• Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr;115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.


• Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene. 2010 Jan;29(2):157-173. Pubmedid: 19855430.


• Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des. 2010 Jan;16(3):268-276. Pubmedid: 20109136.


• Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett. 2009 Aug;125(2):114-118. Pubmedid: 19555720. Pmcid: PMC2758552.


• Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 Aug;15(10):3406-3415. Pubmedid: 19401350.


• Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther. 2009 Jul;8(13):1273-1280. Pubmedid: 19440035. Pmcid: PMC2766923.


• Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009 May;182(9):5693-5701. Pubmedid: 19380816. Pmcid: PMC2833019.


• Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan;10(1):92-100. Pubmedid: 19011628.


• Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan;23(1):170-177. Pubmedid: 18843286.


• Zelenetz A, Advani R, Byrd J, Czuczman M, Damon L, Duvic M, Fayad L, Forero A, Glenn M, Gockerman J, Gordon L, Harris N, Hoppe R, Horwitz S, Kaminski M, Kim Y, Lacasce A, Nademanee A, Olsen E, Porcu P, Press O, Prosnitz L, Smith M, Sotomayor E, Vose J, Yahalom J, Yunus F. Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421. Pubmedid: 18433606.


• Villagra A, Ulloa N, Zhang X, Yuan Z, Sotomayor E, Seto E. HDAC3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J Biol Chem. 2007 Dec;282(49):35457-35470. Pubmedid: 17925399.


• Vicente-Suarez I, Takahashi Y, Cheng F, Horna P, Wang HW, Wang HG, Sotomayor EM. Identification of a novel negative role of flagellin in regulating IL-10 production. Eur J Immunol. 2007 Nov;37(11):3164-3175. Pubmedid: 17948265.


• Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep;110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.


• Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul;21(7):1521-1531. Pubmedid: 17476277.


• Horna P, Sotomayor E. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets. 2007 Feb;7(1):41-53. Pubmedid: 17305477.


• Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Ann Surg Oncol. 2007 Feb;14(2):869-884. Pubmedid: 17103257.


• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;233-242. Pubmedid: 18024635.


• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296. Pubmedid: 17134371. Pmcid: PMC2895922.


• Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr;107(7):2871-2878. Pubmedid: 16339406.


• Zelenetz A, Advani R, Buadi F, Cabanillas F, Caligiuri M, Czuczman M, Damon L, Fayad L, Flinn I, Forero A, Glenn M, Gockerman J, Gordon L, HarrisNL, Hoppe R, Kaminski M, Lacasce A, Nademanee A, Porcu P, Press O, ProsnitzL, Smith M, Sotomayor E, Vose J, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Mar;4(3):258-310. Pubmedid: 16507273.


• Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005 Feb;105(3):1135-1143. Pubmedid: 15454486.


• Ghansah T, Paraiso K, Highfill S, Desponts C, May S, McIntosh J, Wang J, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr W. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol. 2004;173(12):7324-7330. Pubmedid: 15585856.


• Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839-5849. Pubmedid: 15313928.


• Cheng F, Gabrilovich D, Sotomayor E. Immune tolerance in breast cancer. Breast Dis. 2004;20:93-103. Pubmedid: 15687711.


• Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. Mol Biotechnol. 2003 Oct;25(2):139-148. Pubmedid: 14526124.


• Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. An introduction. Methods Mol Med. 2003;75:529-543. Pubmedid: 12407762.


• Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr W, TakedaK, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19(3):425-436. Pubmedid: 14499117.


• Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, Gabrilovich D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res. 2003;9(1):285-294. Pubmedid: 12538481.


• Kusmartsev S, Cheng F, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441-4449. Pubmedid: 12907617.


• Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello I, Levitsky H, Sotomayor E. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003;63(24):9007-9015. Pubmedid: 14695219.


• Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM. Advances in gene therapy for malignant melanoma. Cancer Control. 2002 Jan;9(1):39-48. Pubmedid: 11907465.


• Sotomayor E, Piantadosi S, Miller C, Karp J, Jones R, Rowley S, Kaufmann S, Braine H, Burke P, Gore S. Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk Res. 2002;26(5):461-471. Pubmedid: 11916520.


• Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora L, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton W, Jove R, Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 2002;1(11):893-899. Pubmedid: 12481410.


• Borrello I, Sotomayor E. Cancer vaccines for hematologic malignancies. Cancer Control. 2002;9(2):138-151. Pubmedid: 11965234.


• Sotomayor E, Loughran T. Immunotherapy of hematologic malignancies: the road to the future. Cancer Control. 2002;9(2):97-98. Pubmedid: 11965230.


• Sotomayor E, Borrello I, Rattis F, Cuenca A, Abrams J, Staveley K, Levitsky H. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001;98(4):1070-1077. Pubmedid: 11493453.


• Gabrilovich D, Veldwers M, Sotomayor E, Kast W. Mechanisms of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166(9):5398-5406. Pubmedid: 11313376.


• Antonia SJ, Sotomayor E. Gene therapy for lung cancer. Curr Opin Oncol. 2000 Mar;12(2):138-142. Pubmedid: 10750725.


• Borrello I, Sotomayor E, Rattis F, Cooke S, Gu L, Levitsky H. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 2000;95(10):3011-3019. Pubmedid: 10807763.


• Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky H, Pardoll D. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med. 2000;191(3):541-550. Pubmedid: 10662799.


• Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A. 1999 Sep;96(20):11476-11481. Pubmedid: 10500201. Pmcid: PMC18058.


• Borrello I, Sotomayor, M.D. E, Cooke S, Levistsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 1999;10(12):1983-1991. Pubmedid: 10466632.


• Sotomayor, M.D. E, Borrello I, Tubb E, Rattis F, Bien H, Lu Z, Fein S, Schoenberger S. Conversion of tumor-specific CD4+ T cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780-787. Pubmedid: 10395323.


• Sotomayor, M.D. E, Stavely-O'Carroll, K, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998;95:1178-1183. Pubmedid: 9448305.


• Sotomayor E, Borrello I, Levitsky H. Tolerance and cancer:a critical issue in tumor immunology. Crit Rev Onco. 1996;7(5):433-456. Pubmedid: 9467666.


• Sotomayor E, Dinapoli M, Calderon C, Colsky A, Fu Y, Lopez D. Impaired macrophage mediated cytotoxicity in mammary tumor bearing mice is related to alteration in nitric oxide production and/or release. Int J Cancer. 1995;60:660-667. Pubmedid: 7860141.


• Sotomayor EM, Rao K, Lopez DM, Liepins A. Enhancement of macrophage tumouricidal activity by the alkaloid derivative Ukrain. In vitro and in vivo studies. Drugs Exp Clin Res. 1992;18 Suppl:5-11. Pubmedid: 1305044.

Dr. Eduardo Sotomayor is the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center.  He is a professor of oncology and a professor of pathology and cell biology at the University of South Florida College of Medicine
Dr. Sotomayor’s primary area of research is immunotherapy of B-cell malignancies with special emphasis on the design of novel cancer vaccines and monoclonal antibodies. Clinically, Dr. Sotomayor has a particular interest in mantle cell lymphoma (MCL), an aggressive type of B-cell non-Hodgkin lymphoma.  He has several ongoing phase I and II clinical trial for patients with this type of lymphoma.
A graduate of Federico Villarreal National University School of Medicine in Lima, Peru, Dr. Sotomayor completed his residency in internal medicine at Jackson Memorial Medical Center and the University of Miami School of Medicine.  He pursued a fellowship in medical oncology from Johns Hopkins University School of Medicine and a postdoctoral research fellowship in microbiology and immunology at the University of Miami.
Dr. Sotomayor joined Moffitt in 1999.  He is the recipient of numerous awards, including Celgene’s Young Investigator Achievement Award in Hematology.  He is widely published and is a member of the American Society of Clinical Oncology, American Association for Cancer Research, among other professional organizations.